OBJECTIVE: To test the hypothesis that rapamycin inhibits induced microvascular hyperpermeability directly in vivo. METHODS: Male golden Syrian hamsters (80-120 g) were treated with either rapamycin (at 0.1, 0.5, 2, and 10 mg/kg i.p.) or vehicle at 24 hours and at 1 hour prior to preparation of the cheek pouch. Caveolin-1 scaffolding (1 mg/kg; positive inhibitory control) was injected i.p. 24 hours prior to the experiment. 10(-8) M vascular endothelial growth factor (VEGF) or 10(-7) M platelet-activating factor (PAF) were topically applied to the cheek pouch. Microvascular permeability and arteriolar diameter were assessed using integrated optical intensity (IOI) and vascular wall imaging, respectively. RESULTS: Rapamycin at 0.1 and 0.5 mg/kg significantly reduced VEGF-stimulated mean IOI from 63.0 +/- 4.2 to 9.7 +/- 5.0 (85% reduction, P < 0.001) and 3.6 +/- 2.7 (95% reduction, P < 0.001), respectively. Rapamycin at 2 mg/kg also lowered VEGF-stimulated hyperpermeability (40% reduction, P < 0.05). However, 10 mg/kg rapamycin increased VEGF-induced microvascular hyperpermeability. Rapamycin at 0.5 mg/kg attenuated VEGF-induced vasodilation and PAF-induced hyperpermeability, but did not inhibit PAF-induced vasoconstriction. CONCLUSIONS: At therapeutically relevant concentrations, rapamycin inhibits VEGF- and PAF-induced microvascular permeability. This inhibition is (i) a direct effect on the endothelial barrier, and (ii) independent of arteriolar vasodilation. Rapamycin at 10 mg/kg stimulates effectors that increase microvascular permeability.
OBJECTIVE: To test the hypothesis that rapamycin inhibits induced microvascular hyperpermeability directly in vivo. METHODS: Male golden Syrian hamsters (80-120 g) were treated with either rapamycin (at 0.1, 0.5, 2, and 10 mg/kg i.p.) or vehicle at 24 hours and at 1 hour prior to preparation of the cheek pouch. Caveolin-1 scaffolding (1 mg/kg; positive inhibitory control) was injected i.p. 24 hours prior to the experiment. 10(-8) M vascular endothelial growth factor (VEGF) or 10(-7) M platelet-activating factor (PAF) were topically applied to the cheek pouch. Microvascular permeability and arteriolar diameter were assessed using integrated optical intensity (IOI) and vascular wall imaging, respectively. RESULTS:Rapamycin at 0.1 and 0.5 mg/kg significantly reduced VEGF-stimulated mean IOI from 63.0 +/- 4.2 to 9.7 +/- 5.0 (85% reduction, P < 0.001) and 3.6 +/- 2.7 (95% reduction, P < 0.001), respectively. Rapamycin at 2 mg/kg also lowered VEGF-stimulated hyperpermeability (40% reduction, P < 0.05). However, 10 mg/kg rapamycin increased VEGF-induced microvascular hyperpermeability. Rapamycin at 0.5 mg/kg attenuated VEGF-induced vasodilation and PAF-induced hyperpermeability, but did not inhibit PAF-induced vasoconstriction. CONCLUSIONS: At therapeutically relevant concentrations, rapamycin inhibits VEGF- and PAF-induced microvascular permeability. This inhibition is (i) a direct effect on the endothelial barrier, and (ii) independent of arteriolar vasodilation. Rapamycin at 10 mg/kg stimulates effectors that increase microvascular permeability.
Authors: Norio Uchimura; Ganesha B Perera; Roy M Fujitani; Jonathan M Tobis; Shin Ishimaru; Samuel E Wilson; Ian L Gordon Journal: Ann Vasc Surg Date: 2004-03 Impact factor: 1.466
Authors: Gavin Y Oudit; Hui Sun; Benoit-Gilles Kerfant; Michael A Crackower; Josef M Penninger; Peter H Backx Journal: J Mol Cell Cardiol Date: 2004-08 Impact factor: 5.000
Authors: Hani Wadei; Scott A Gruber; Jose M El-Amm; James Garnick; Miguel S West; Darla K Granger; Dale H Sillix; Stephen D Migdal; Abdolreza Haririan Journal: Am J Transplant Date: 2004-06 Impact factor: 8.086
Authors: Haruo Aramoto; Jerome W Breslin; Peter J Pappas; Robert W Hobson; Walter N Durán Journal: Am J Physiol Heart Circ Physiol Date: 2004-05-20 Impact factor: 4.733
Authors: Erich R Mackow; Nadine A Dalrymple; Velasco Cimica; Valery Matthys; Elena Gorbunova; Irina Gavrilovskaya Journal: Virus Res Date: 2014-01-08 Impact factor: 3.303
Authors: David C Fajgenbaum; Ruth-Anne Langan; Alberto Sada Japp; Helen L Partridge; Sheila K Pierson; Amrit Singh; Daniel J Arenas; Jason R Ruth; Christopher S Nabel; Katie Stone; Mariko Okumura; Anthony Schwarer; Fábio Freire Jose; Nelson Hamerschlak; Gerald B Wertheim; Michael B Jordan; Adam D Cohen; Vera Krymskaya; Arthur Rubenstein; Michael R Betts; Taku Kambayashi; Frits van Rhee; Thomas S Uldrick Journal: J Clin Invest Date: 2019-08-13 Impact factor: 14.808
Authors: Seok-Hyung Kim; Marie L Kowalski; Robert P Carson; L Richard Bridges; Kevin C Ess Journal: Dis Model Mech Date: 2013-03-27 Impact factor: 5.758
Authors: Paweł Kolano; Igor A Bednarski; Aleksandra Lesiak; Małgorzata Skibińska; Olga Stasikowska-Kanicka; Marian Danilewicz; Joanna Narbutt Journal: Postepy Dermatol Alergol Date: 2020-05-06 Impact factor: 1.837